These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1000 related items for PubMed ID: 16707453

  • 1. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
    Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, Kurek R, Neubauer HJ.
    Cancer Res; 2006 May 15; 66(10):5278-86. PubMed ID: 16707453
    [Abstract] [Full Text] [Related]

  • 2. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM.
    Breast Cancer Res; 2008 May 15; 10(5):R87. PubMed ID: 18928525
    [Abstract] [Full Text] [Related]

  • 3. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.
    Seth A, Kitching R, Landberg G, Xu J, Zubovits J, Burger AM.
    Anticancer Res; 2003 May 15; 23(3A):2043-51. PubMed ID: 12894577
    [Abstract] [Full Text] [Related]

  • 4. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.
    Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Dürst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ.
    Clin Cancer Res; 2006 Jul 01; 12(13):3950-60. PubMed ID: 16818692
    [Abstract] [Full Text] [Related]

  • 5. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
    Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG, Salto-Tellez M, Putti TC.
    Breast Cancer Res Treat; 2009 Jan 01; 113(1):113-21. PubMed ID: 18256927
    [Abstract] [Full Text] [Related]

  • 6. A SAGE (serial analysis of gene expression) view of breast tumor progression.
    Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, Riggins G, Polyak K.
    Cancer Res; 2001 Aug 01; 61(15):5697-702. PubMed ID: 11479200
    [Abstract] [Full Text] [Related]

  • 7. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 01; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 8. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
    Adams M, Jones JL, Walker RA, Pringle JH, Bell SC.
    Cancer Res; 2002 Jun 01; 62(11):3289-97. PubMed ID: 12036947
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types.
    Iacobuzio-Donahue CA, Argani P, Hempen PM, Jones J, Kern SE.
    Cancer Res; 2002 Sep 15; 62(18):5351-7. PubMed ID: 12235006
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast.
    Schmid BC, Rudas M, Fabjani G, Speiser P, Kaserer K, Leodolter S, Zeillinger R.
    Oncol Rep; 2003 Sep 15; 10(6):1981-5. PubMed ID: 14534730
    [Abstract] [Full Text] [Related]

  • 12. Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast.
    Verlinden I, Janssens J, Raus J, Michiels L.
    Mol Carcinog; 2004 Dec 15; 41(4):197-206. PubMed ID: 15486950
    [Abstract] [Full Text] [Related]

  • 13. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.
    Anticancer Res; 2005 Dec 15; 25(3A):1719-23. PubMed ID: 16033090
    [Abstract] [Full Text] [Related]

  • 14. Increase of GKLF messenger RNA and protein expression during progression of breast cancer.
    Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, Ruppert JM.
    Cancer Res; 2000 Nov 15; 60(22):6488-95. PubMed ID: 11103818
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q.
    Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Rougé C, Ursule L, Nguyen C, Bibeau F, Rodriguez C, Theillet C.
    Br J Cancer; 2006 Nov 20; 95(10):1439-47. PubMed ID: 17060936
    [Abstract] [Full Text] [Related]

  • 17. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
    Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S.
    Oncogene; 2003 Apr 03; 22(13):2021-33. PubMed ID: 12673207
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
    Nielsen BS, Rank F, López JM, Balbin M, Vizoso F, Lund LR, Danø K, López-Otín C.
    Cancer Res; 2001 Oct 01; 61(19):7091-100. PubMed ID: 11585740
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.